Clinical Trial Update: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) [Phase 2]

View source ↗

Summary

Phase 2 CARMEN-LC04 trial evaluating Tusamitamab Ravtansine with Ramucirumab, with or without Pembrolizumab, in pretreated metastatic non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Ramucirumab (ramucirumab)
• Tusamitamab Ravtansine (Tusamitamab Ravtansine)

Snippet

Sponsor: Sanofi | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2024-03-28